Shutterstock.com_1714981606/Nadya So

12 August 2025Reinsurance

Life insurance applicants increasingly using longevity drugs, warns Swiss Re

Repurposed drugs used for longevity are gaining popularity, according to global reinsurance group Swiss Re, prompting it to introduce guidance for underwriters on how to assess life insurance applicants who show signs of their use.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Convex founder Catlin stands down as chair, Onex CEO takes role

25 March 2026 Founder moves into life president role, retaining strategic and mentoring duties.

Wawanesa to score $305m premium bump from Everest Canada buy

25 March 2026 Deal ‘especially accretive’ to programmes, opens new markets for Wawanesa: AM Best.

Ariel Re promotes across global business to support talent strategy

24 March 2026 Promotions span underwriting, analytics and operations teams.

More articles

US GenAI lawsuits surge nearly 1000% from 2012 to 2025: Gallagher Re

MS Amlin filters market noise, doubles down on reinsurance strategy

Swiss Re to tap reserves, Scor and Prudential eye capital upside: UBS

Sustained underwriting pressure a headwind for UK non-life insurers: AM Best

Three quarters of UK insurers use generative AI: Gallagher Bassett

Reinsurance’s liquidity problem is structural: Howden

Mercer boosts private markets capabilities with specialist buy

Canopius lines up Scor, ex-Marsh duo for global claims leadership

Copyright © intelligentinsurer.com 2024 | Headless Content Management with Blaze